Preview

Общая реаниматология

Расширенный поиск

ПРЕПАРАТЫ ЛЕГОЧНОГО СУРФАКТАНТА ПРИ ОСТРЫХ И ХРОНИЧЕСКИХ ЗАБОЛЕВАНИЯХ ЛЕГКИХ (Часть I)

https://doi.org/10.15360/1813-9779-2014-4-51-73

Полный текст:

Аннотация

В первой части обзора приводятся сведения о составе и свойствах легочного сурфактанта, количественных и качественных нарушениях сурфактантной системы легких при различных патологических состояниях новорожденных и взрослых, описывается состав коммерческих синтетических и природных препаратов сурфактанта. Проводится анализ результатов сурфактанттерапии РДС и других заболеваний легких с вторичным дефицитом сурфактанта у новорожденных.

Об авторе

О. А. Розенберг
Российский научный центр радиологии и хирургических технологий Минздрава России, Санкт-Петербург
Россия


Список литературы

1. King R.J., Clements J.A. Surface active materials from dog lung: composition and physiological correlations. Am. J. Physiol. 1972; 223 (3): 715—726. PMID: 506862

2. Avery M.E., Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am. J. Dis. Child. 1959; 97 (5 Pt 1): 517—523. http://dx.doi.org/10.1001/archpedi.1959.02070010519001.PMID: 13649082

3. Volodin N.N., Degtyarev D.N., Babak O.A., Levadnaya A.V. Ispolzovanie ekzogennogo surfaktanta u nedonoshennykh detei pri bronkholegochnoi displazii. [Use of exogenous surfactant in premature infants with bronchopulmonary dysplasia]. Vestnik Rossiiskogo Gosudarstvennogo Meditsinskogo Universiteta. 2010; 2: 41—46. [In Russ.]

4. Ashbaugh D.G., Bigelow D.B., Petty T.L., Levine B.E. Acute respiratory distress in adults. Lancet. 1967; 290 (7511): 319—323. http://dx.doi.org/10.1016/S01406736(67)901687. PMID: 16548822

5. Lewis J.F., Jobe A.H. Surfactant and the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1993; 147 (1): 218—233. http://dx.doi.org/10.1164/ajrccm/147.1.218. PMID: 8420422

6. Schmidt R., Meier U., Yabut Perez M., Walmrath D., Grimminger F., Seeger W., Günther A. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and pneumonia. Am. J. Resp. Сrit. Care Med. 2001; 163 (1): 95—100.

7. http://dx.doi.org/10.1164/ajrccm.163.1.9903029. PMID: 11208632

8. Baughman R.P., Stein E., MacGee J., Rashkin M., Sahebjami H. Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin. Chem. 1984; 30 (4): 521—525. PMID: 6705194

9. Baughman R.P., Sternberg R.I., Hull W., Buchsbaum J.A., Whitsett J. Decreased surfactant protein A in patients with bacterial pneumonia. Am. Rev. Respir. Dis. 1993; 147 (3): 653657. http://dx.doi.org/10.1164/ajrccm/147.3.653. PMID: 8442601

10. Günther A., Siebert C., Schmidt R., Ziegler S., Grimminger F., Yabut M., Temmesfeld B., Walmrath D., Morr H., Seeger W. Surfactant alterations in severe pneumonia, ARDS and cardiogenic lung edema. Am. J. Resp. Crit. Care Med. 1996; 153 (1): 176—184. http://dx.doi.org/10.1164/ajrccm.153.1.8542113. PMID: 12030716

11. Lewis J.F., Veldhuizen R. The role of exogenous surfactant in the treat ment of acute lung injury. Annu. Rev. Physiol. 2003; 65: 613642. PMID: 12517997

12. Griese M., Birrer P., Demirsoy A. Pulmonary surfactant in cystic fibro sis. Eur. Respir. J. 1997; 10 (9): 1983—1997. http://dx.doi.org/10.1183/09031936.97.10091983. PMID: 9311489

13. Bredow C., Birrer P., Griese M. Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur. Respir. J. 2001; 17 (4): 716—724. PMID: 11401069

14. McCormack F.X., King T.E. Jr., Voelker D.R., Robinson P.C., Mason R.J. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am. Rev. Respir. Dis. 1991; 144 (1): 160—169. http://dx.doi.org/10.1164/ajrccm/144.1.160. PMID: 2064123

15. Robinson P.C., Watters L.C., King T.E., Mason R.J. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage fluid phospholipids. Am. Rev. Respir. Dis. 1988; 137 (3): 585—592. http://dx.doi.org/10.1164/ajrccm/137.3.585. PMID: 3345040

16. Oyarzun M.J., Stevens P., Clemens J.A. Effect of lung collapse on alveolar surfactant in rabbits subjected to unilateral pneumothorax. Exp. Lung. Res. 1990; 15 (6): 909924. http://dx.doi.org/10.3109/01902148909069635. PMID: 2612447

17. Hallman M., Maasilta P., Kivisaari L., Mattson K. Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am. Rev. Respir. Dis. 1990; 141 (4 Pt 1): 998—1007. http://dx.doi.org/10.1164/ajrccm/141.4_Pt_1.998. PMID: 2327659

18. Pniewska E., Pawliczak R. The involvement of phospholipases A2 in asthma and chronic obstructive pulmonary disease. Mediators Inflamm. 2013; 2013: 793505. http://dx.doi.org/10.1155/2013/793505. PMID: 24089590

19. Cheng G., Ueda T., Numao T., Kuroki Y., Nakajima H., Fukushima Y., Motojima S., Fukuda T. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J. 2000; 16 (5): 831835. http://dx.doi.org/10.1183/09031936.00.16583100. PMID: 11153579

20. Haczku A., Atochina E.N., Tomer Y., Cao Y., Campbell C., Scanlon S.T., Russo S.J., Enhorning G., Beers M.F. The late asthmatic response is linked with increased surface tension and reduced surfactant protein B in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2002; 283 (4): 755—760. PMID: 12225952

21. Hohlfeld J.M., Ahlf K., Enhorning G., Balke K., Erpenbeck V.J., Petschallies J., Hoymann H.G., Fabel H., Krug N. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge.

22. Am. J. Respir. Crit. Care Med. 1999; 159 (6): 1803—1809. http://dx.doi.org/10.1164/ajrccm.159.6.9806145. PMID: 10351922

23. Hohlfeld J.M., Schmiedl A., Erpenbeck V.J., Venge P., Krug N. Eosiniphil cationic protein (ECP) alters pulmonary structure and function in asthma. J. Allergy Clin. Immunol. 2004; 113 (3): 496—502. PMID: 15007353

24. Wang J.Y., Shieh C.C., Yu C.K., Lei H.Y. Allergeninduced bronchial inflammation is associated with decreased levels of surfactant proteins A and D in a murine model of asthma. Clin. Exp. Allergy. 2001; 31 (4): 652—662. http://dx.doi.org/10.1046/j.13652222.2001.01031.x. PMID: 11359435

25. Wright S.M., Hockey P.M., Enhorning G., Strong P., Reid K.B., Holgate S.T., Djukanovic R., Postle A.D. Altered airway surfactant phospholipids composition and reduced lung function in asthma. J. Appl. Physiol. (1985). 2000; 89 (4): 12831292. PMID: 11007560

26. Devendra G., Spragg R.G. Lung surfactant in subacute pulmonary disease. Respir. Res. 2002; 3: 1930. http://dx.doi.org/10.1186/rr168. PMID: 11980588

27. Günther A., Schmidt R., Nix F., Yabut Perez M., Guth C., Rosseau S., Siebert C., Grimminger F., Morr H., Velcovsky H.G., Seeger W. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur. Respir. J. 1999; 14 (3): 565—573.

28. http://dx.doi.org/10.1034/j.13993003.1999.14c14.x. PMID: 10543276

29. Erokhin V.V. Morfofunktsionalnoe sostoyanie kletok legkikh prituberkuleznom vospalenii. V kn.: Erokhin V.V., Romanova L.K. (red.). Kletochnaya biologiya legkikh v norme i pri patologii. Rukovodstvo dlya vrachei. [Morphofunctional state of lung cells in tuberculous inflammation. In: Erokhin V.V., Romanova L.K. (eds.). Lung cellular biology in health and disease. A manual for physicians]. Moscow: Meditsina Publishers; 2000: 496—518. [In Russ.]

30. Erokhin V.V.., Romanova L.K. Surfaktantnaya sistema legkikh. V kn.: Erokhin V.V., Romanova L.K. (red.). Kletochnaya biologiya legkikh v norme i pri patologii. Rukovodstvo dlya vrachei. [Pulmonary surfac tant system. In: Erokhin V.V., Romanova V.V. (eds.). Lung cellular biology in health and disease. A manual for physicians]. Moscow: Meditsina Publishers; 2000: 167—181. [In Russ.]

31. Lepekha L.N. Surfaktantnaya sistema legkikh pri eksperimentalnom tuberkuleze i otsenka ee morfofunktsionalnogo sostoyaniya u chelove ka: avtoref. dis. … dra biol. nauk. [Pulmonary surfactant system in experimental tuberculosis and evaluation of its morphological status in man: Abstract of Biol. Doctoral Thesis]. Moscow, 1995: 44. [In Russ.]

32. Rosenberg O., Bautin A., Osovskich V., Kozlov I., Erochin V., Tarasenko M., Lovacheva O., Lepekha L., Seiliev A., Volchkov V. Surfactant therapy for acute and chronic lung diseases. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 78—78.

33. Fujiwara T., Maeta H., Chida S., Morita T., Watabe Y., Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet. 1980; 1 (8159): 5559. http://dx.doi.org/10.1016/S01406736 (80)904894. PMID: 6101413

34. Lachmann B. Surfactant replacement in acute respiratory failure: Animal studies and first clinical trials. In: Lachmann B. (ed.). Surfactant replacement therapy. New York: SpringerVerlag; 1987: 212—220.

35. Spragg R.G. Current status of surfactant treatment of ARDS/ALI. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 88—90.

36. Gregory T.J., Steinberg K.P., Spragg R., Gadek J.E., Hyers T.M., Longmore W.J., Moxley M.A., Cai G.Z., Hite R.D., Smith R.M., Hudson L.D., Crim C., Newton P., Mitchell B.R., Gold A.J. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1997; 155 (4): 13091315. http://dx.doi.org/10.1164/ajrccm.155.4.9105072. PMID: 9105072

37. Rosenberg O.A., Bautin A.E., Osovskich V.V., Tsibulkin E.K., Gavrilin S.V., Kozlov I.A. When to start surfactant therapy (STtherapy) of acute lunginjury? Abstracts 11th ERS Annual Congress. Berlin, Germany, September 2226, 2001. Eur. Respir. J. 2001; 18 (Suppl 38): P153, 7s.

38. Anzueto A., Baughman R.P., Guntupalli K.K., Weg J.G., Wiedemann H.P., Raventós A.A., Lemaire F., Long W., Zaccardelli D.S., Pattishall E.N. Aerosolized surfactant in adults with septicinduced acute respiratory distress syndrome. N. Engl. J. Med. 1996; 334 (22): 14171421. PMID: 8618579

39. Willson D.F., Thomas N.J., Markovitz B.P., Bauman L.A., DiCarlo J.V., Pon S., Jacobs B.R., Jefferson L.S., Conaway M.R., Egan E.A. Pediatric acute lung injury and sepsis investigators. Effect of exogenous surfactant (Calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005; 293 (4): 470—476. PMID: 15671432

40. Tsybulkin E.K., Rozenberg A.O., Seiliev A.A., Volchkov V.A., Zaitseva N.I., Kuzmenko I.G., Loshakova L.V., Pelogievskaya Z.I., Portnyagin I.V., Shefer S.P., Shulga A.E. Opyt primeneniya otechestvennogo preparata legochnogo surfaktanta dlya lecheniya sindroma dykhatelnykh rasstroistv vzroslykh i tyazhelykh pnevmonii u detei. [Our experience in the use of a Russian preparation of pulmonary surfactant in the treatment of acute respiratory distress syndrome and severe pneumonia in children]. Anesteziologiya i Reanimatologiya. 1999; 2: 6165. PMID: 10360078. [In Russ.]

41. Bautin A.E., Osovskikh V.V., Khubulava G.G., Granov D.A., Kozlov I.A., Erokhin V.V., Likhvantsev V.V., Tsarenko S.V., Kazennov V.V., Zhilin Yu.N., Poptsov V.N., Shulga A.E., Kirillov Yu.A., Seiliev A.A., Volchkov V.A., Rozenberg A.O. Mnogotsentrovye klinicheskie ispytaniya surfak tantaBL dlya lecheniya respiratornogo distresssindroma vzroslykh. [Multicenter clinical trials of surfactantBL for the treatment of adult respiratory distress syndrome]. Klinicheskie Issledovaniya Lekarstvennykh Sredstv v Rossii. 2002; 2: 18—23. [In Russ.]

42. Alekseyev A.M., Shupinsky O.V., Khrapov K.N. Intensivnaya terapiya bolnykh s tyazhelym techeniem grippa A (H1N1), oslozhnennogo pnevmoniei. [Intensive therapy in patients with severe influenza A (H1N1) complicated by pneumonia]. Vestnik Anesteziologii i Reanimatologii. 2009; 6 (6): 35—39. [In Russ.]

43. Alekseyev A.M., Yakovlev A.A., Shvechkova M.V., Seiliev A.A., Volchkov V.A., Rozenberg A.O. Surfaktantterapiya pnevmonii i ORDS, assotsi irovannykh s virusom A/H1N1. [Surfactant therapy for A/H1N1 virusassociated pneumonia and ARDS]. Zabaikalsky Meditsinsky Zhurnal. 2011; 1: 2327. [In Russ.]

44. Rosenberg O., Alekseev A., Iakovlev A., Shvechkova M., Seiliev A., Volchkov V. Surfactant therapy of A/H1N1 severe pneumonia and ARDS is a chance for survival. Abstract 20th Annual Congress. Barselona, Spain, September 1822, 2010. Eur. Respir. J. 2010; 56 (Suppl 54): P4261, 772 s.

45. Antonov A.G. Zabolevaniya bronkholegochnoi sistemy u nedonoshen nykh detei. V kn.: Sidelnikova V.M., Antonov A.G. (red.). Prezhdevremennye rody. Nedonoshennyi rebenok. Rukovodstvo dlya vrachei. [Bronchopulmonary system diseases in premature infants. In: Sidelnikova V.M., Antonov A.G. (eds.). Preterm delivery. A premature baby. A manual for physicians]. Moscow: GEOTARMedia; 2006: 327—354. [In Russ.]

46. Antonov A.G., Ryndin A.Yu. Surfaktant BL v kompleksnoi terapii respiratornykh narushenii u novorozhdennykh detei. [SurfactantBL in the combination therapy of neonatal respiratory disorders]. VoprosyPrakticheskoi Pediatrii. 2007; 2 (4): 61—64. [In Russ.]

47. Ivanov D.O., Petrenko Yu.V. (red.). Sovremennye aspekty organizatsii neonatalnoi pomoshchi. Rukovodstvo dlya vrachei. [Current aspects of neonatal care delivery. A manual for physicians]. SanktPeterburg: izs vo N—L; 2011: 465. [In Russ.]

48. Bonc^uk Dayanikli P., Taeusch W.H. Essential and nonessential constituents of exogenous surfactants. In: Robertson B., Taeusch H.W. (eds.). Surfactant therapy for lung disease. Lung biology in health and disease. vol. 84. NewYork: Marcel Dekker Inc; 1995: 217—238.

49. Günther A., Ruppert C., Schmidt R., Markart P., Grimminger F., Walmrath D., Seeger W. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir. Res. 2001; 2 (6): 353—364. PMID: 11737935

50. Sanders R.L. The composition of pulmonary surfactant. In: Farrell P.M. (ed.). Lung development: Biological and clinical perspectives. vol. 1. New York: Academic Press; 1982: 193—210.

51. Possmayer F. A proposed nomenclature for pulmonary surfactantasso ciated proteins. Am. Rev. Respir. Dis. 1988; 138 (4): 990998. http://dx.doi.org/10.1164/ajrccm/138.4.990. PMID: 3059887

52. Persson A., Chang D., Rust K., Moxley M., Longmore W., Crouch E. Purification and biochemical characterization of CP4 (SPD), a collagenous surfactantassociated protein. Biochemistry. 1989; 28 (15): 63616367. http://dx.doi.org/10.1021/bi00441a031. PMID: 2675969

53. Knoor A., Gray M.E., Hull W.M., Whitsett J.A., Stahlman M.T. Developmental expression of SPA and SPA mRNA in the proximal and distal respiratory epithelium in the human fetus and newborn. J.Histochem. Cytochem. 1993; 41 (9): 1311—1319. PMID: 8354874

54. Madsen J., Kliem A., Tornoe I., Skjodt K., Koch C., Holmskov U. Localization of lung surfactant protein D on mucosal surface in human tissue. J. Immunol. 2000; 164 (11): 5866—5870. http://dx.doi.org/10.4049/jimmunol.164.11.5866. PMID: 10820266

55. Rozenberg O.A. Legochnyi surfactant i ego primenenie pri zabolevaniyakh legkikh. Obshchaya Reanimatologiya. [Lung surfactant and its use in lung diseases. General Reanimatology]. 2007; 3 (1): 66—77. [In Russ.]

56. Bangham A.D. Artificial lung expanding compound (ALECtm). In: Lasic D.D., Papahajopoulos D. (eds.). Medical applications of liposomes. Elsevier Science; 1998: 452—455. http://dx.doi.org/10.1016/B9780444829177/500260

57. Floros J., Phelps D.S., Pison U., Spragg R. Pulmonary surfactantupdate on function, molecular biology and clinical implications. Cur. Respir. Med. Rev. 2005; 1 (1): 77—84. http://dx.doi.org/10.2174/1573398052953631

58. Clements J.A. Surface tension of lung extracts. Proc. Soc. Exp. Biol. Med. 1957; 95 (1): 170172. http://dx.doi.org/10.3181/0037972795 23156. PMID: 13432025

59. Schürch S., Bachofen H. Biophysical aspects in the design of a therapeutic surfactant. In: Robertson B., Taeush H.W. (eds.). Surfactant therapy for lung disease. Lung biology in health and disease. vol. 84. New York: Marcel Dekker Inc; 1995: 3—26.

60. Horie T., Hildebrandt J. Dynamic compliance, limit cycles and static equilibria of excised cat lung. J. Appl. Physiol. 1971; 31 (3): 423—428. PMID: 5111861

61. Mead J., Collier C. Relation of volume history of lungs to respiratory mechanics in anesthetized dogs. J. Appl. Physiol. 1959; 14: 669—675. http://dx.doi.org/10.1097/0013258619610200000007.

62. Rosenberg O., Seiliev A., Zhuikov A. Lung surfactant: correlation between biophysical characteristic, composition, and therapeutic efficacy. In: Gregoriadis G. (ed.). Liposome Technology. 3rd ed. vol. 3. ch. 17. Informa Healthcare; 2006: 317—345.

63. Bachofen H., Schürch S., Urbinelli M., Weibel E.R. Relations among alveolar surface tension, surface area, volume and recoil pressure. J. Appl. Physiol. 1987; 62 (5): 1878—1891. PMID: 3597262

64. Schürch S., Goerke J., Clements J.A. Direct determination of volume and timedependence of alveolar surface tension in excised lungs. Proc. Natl. Acad. Sci. USA. 1978; 75 (7): 3417—3420. PMID: 277943

65. Willson T.A., Bachofen H.A model for mechanical structure of the alveolar duct. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1982; 52 (4):10641070. PMID: 7085408

66. Bachofen H., Schürch S., Michel R.P., Weibel E.R. Experimental hydrostatic pulmonary edema in rabbit lungs. Morphology. Am. Rev. Respir. Dis. 1993; 147 (4): 989—996. http://dx.doi.org/10.1164/ajrccm/147.4.989. PMID: 8466138

67. Bachofen H., Schürch S., Weibel I.R. Experimental hydrostatic pulmonary edema in rabbit lungs. Barrier lesions. Am. Rev. Respir. Dis. 1993; 147 (4): 997—1006. http://dx.doi.org/10.1164/ajrc cm/147.4.997. PMID: 8466139

68. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1998; 1408 (23): 79—89. http://dx.doi.org/10.1016/S09254439(98)00060X. PMID: 9813251

69. Bates S.R., Ibach P.B., Fisher A.B. Phospholipids coisolated with rat surfactant protein C account for the apparent proteinenhanced uptake of liposomes into lung granular pneumocytes. Exp. Lung Res. 1989; 15 (5): 695—708. http://dx.doi.org/10.3109/01902148909062855. PMID: 2806192

70. Cocksgutt A., Absolom D., Possmayer F. The role of palmitic acid in pulmonary surfactant: enhancement of surface activity and prevention of inhibition by blood proteins. Biochim. Biophys. Acta 1991; 1085 (2): 248—256. http://dx.doi.org/10.1016/00052760(91)90101M. PMID: 1892895

71. Orgeig S., Daniels C.B. The roles of cholesterol in pulmonary surfactant: insights from comparative and evolutionary studies. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 2001; 129 (1): 75—89. http://dx.doi.org/10.1016/S10956433(01)003075. PMID: 11369535

72. La Force F.M., Kelley W.J., Huber J.L. Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material. Am. Rev. Respir. Dis. 1973; 108 (4): 784—790. PMID: 4582433

73. van Iwaarden F.J., van Golde L.M.J. Pulmonary surfactant and lungdefense. In: Robertson B., Taeusch H.W. (eds.). Surfactant therapy for lung disease. Lung biology in health and disease. vol. 84. New York: Marcel Dekker Inc; 1995: 75—84.

74. van Iwaarden J.F., Claassen E., Jeurissen S.H., Haagsman H.P., Kraal G. Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am. J. Respir. Cell Mol. Biol. 2001; 24 (4): 452—458. http://dx.doi.org/10.1165/ajrcmb.24.4.4239. PMID: 11306439

75. Ikegami M. SPB protects lung from inflammation. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 45—47.

76. Miles P.R., Bowman L., Rao K.M., Baatz J.E., Huffman L. Pulmonary surfactant inhibits LPSinduced nitric oxide production by alveolar macrophages. Am. J. Physiol. 1999; 276 (1 Pt 1): 186—196. PMID: 9887071

77. Crouch E., Wright J.R. Surfactant proteins A and D and pulmonary host defense. Ann. Rev. Physiol. 2001; 63: 521—534. PMID: 11181966

78. Erpenbeck V.J., Malherbe D.C., Sommer S. Surfactant protein D regulates phagocytosis of Grass pollenderived starch granules by alveolar macrophages. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 31—32.

79. Hawgood S. The hydrophilic surfactant protein SPA: Molecular biology, structure and function. In: Robertson B., Van Golde L.M.G., Batenburg J.J. (eds.). Pulmonary surfactant: From molecular biology to clinical practice. Amsterdam: Elsevier; 1992: 33—54.

80. Phelps D.S. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr. Pathol. Mol. Med. 2001; 20 (4): 269—274.

81. http://dx.doi.org/10.1080/152279501750412225. PMID: 11486734

82. Clark H., Palaniyar N., Strong P., Edmondson J., Hawgood S., Reid K.B. Surfactant protein reduces alveolar macrophage apoptosis in vivo. J. Immunol. 2002; 169 (6): 2892—2899. http://dx.doi.org/10.4049/jimmunol.169.6.2892. PMID: 12218102

83. Lewis J., Veldhuizen R. The role of surfactant in the pathophysiology of acute lung injury. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 53—55.

84. Clark J.C., Wert S.E., Bachurski C.J., Stahlman M.T., Stripp B.R., Weaver T.E., Whitsett J.A. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc. Natl. Acad. Sci. USA. 1995; 92 (17): 7794—7798.

85. http://dx.doi.org/10.1073/pnas.92.17.7794. PMID: 7644495

86. Nogee L.M., Garnier G., Dietz H.C., Singer L., Murphy A.M., deMelloD.E., Colten H.R. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kind reds. J. Clin. Invest. 1994; 93 (4): 1860—1863. PMID: 8163685

87. Melton K.R., Nesslein L.L., Ikegami M., Tichelaar J.W., Clark J.C., Whitsett J.A., Weaver T.E. SPB deficiency causes respiratory failure in adult mice. Am. J. Physiol. 2003; 285 (3): 543—549. PMID: 12639841

88. Cochrane C.G. A critical examination of the role of SPB in alveolar expansion. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 27—29.

89. Weaver T.E., Conkright J.J. Function of surfactant proteins B and C. Annu. Rev. Physiol. 2001; 63: 555—578. PMID: 11181967

90. Reinish M.S., Rozenberg O.A. Bystryi metod opredeleniya fosfolipidov v amnioticheskoi zhidkosti. [Rapid method of determination of phospholipid content in the amniotic fluid]. Laboratornoe Delo. 1978; 2: 98—100. PMID: 76014. [In Russ.]

91. Cogo P.E., Zimmermann L.J., Pesavento R., Sacchetto E., Burighel A., Rosso F., Badon T., Verlato G., Carnielli V.P. Surfactant kinetics in preterm infants on mechanical ventilation who did and did not develop bronchopulmonary dysplasia. Crit. Care Med. 2003; 1 (5): 1532—1538. http://dx.doi.org/10.1097/01.CCM.0000063043.25167.99. PMID: 12771629

92. Awasthi S., Coalson J.J., Crouch E., Yang F., King R.J. Surfactant proteins A and D in premature baboons with chronic lung injury(Bronchopulmonary dysplasia). Evidence for an inhibition of secretion. Am. J. Respir. Crit. Care Med. 1999; 160 (3): 942—949.

93. http://dx.doi.org/10.1164/ajrccm.160.3.9806061. PMID: 10471623

94. Ballard P.L., Merrill J.D., Truog W.E., Godinez R.I., Godinez M.H., McDevitt T.M., Ning Y., Golombek S.G., Parton L.A., Luan X., Cnaan A., Ballard R.A. Surfactant function and composition in premature infants treated with inhaled nitric oxide. Pediatrics. 2007; 120 (2): 346—353.

95. http://dx.doi.org/10.1542/peds.20070095. PMID: 17671061

96. Sidorova I.S., Makarov I.O., Edokova A.B., Makarova I.I. O riske razvitiya aspiratsionnogo sindroma u novorozhdennylh. [Risk for neonatalaspiration syndrome]. Rossiisky Vestnik Perinatologii i Pediatrii. 2000; 45 (3): 13—16. [In Russ.]

97. Volodin N.N. (red.). Neonatologiya. Natsionalnoe rukovodstvo. [Neonatology. National guide]. Moscow: GEOTAR—Media; 2007: 848. [In Russ.]

98. Shabalov N.P. Neonatologiya. Uchebnoe posobie. t.1. 3e izd. [Neonatology. A textbook. v. 1, 3rd ed.]. Moscow: MEDpressInform; 2004: 608. [In Russ.]

99. Greene K.E., Wright J.R., Steinberg K.P., Ruzinski J.T., Caldwell E., Wong W.B., Hull W., Whitsett J.A., Akino T., Kuroki Y., Nagae H., Hudson L.D., Martin T.R. Serial changes in surfactantassociated proteins in lung and serum before and after onset of ARDS. Am. J. Resp. Crit. Care Med. 1999; 160 (6): 843—1850. http://dx.doi.org/10.1164/ajrccm.160.6.9901117. PMID: 10588595

100. Schmidt R., Markart P., Ruppert C., Wygrecka M., Kuchenbuch T., Walmrath D., Seeger W., Güenther A. Timedependent changes in pulmonary surfactant function and composition in ARDS due to pneumonia or aspiration. Respir. Res. 2007; 8: 55—66. PMID: 17662121

101. Pison U., Seeger W., Buchhorn R., Joka T., Brand M., Obertacke U., Neuhof H., Schmit Neuerburg K.P. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am. Rev. Respir. Dis. 1989; 140 (4): 1033—1039. http://dx.doi.org/10.1164/ajrccm/140.4.1033. PMID: 2802366

102. Hillman N.H., Kallapur S.G., Pillow J.J., Nitsos I., Polglase G.R., Ikegami M., Jobe A.H. Inhibitors of inflammation and endogenous surfactant pool size as modulators of lung injury with initiation of ventilation in preterm sheep. Respir. Res. 2010; 11: 151—160. http://dx.doi.org/10.

103. /1465992111151. PMID: 21034485

104. Schmidt R., Meier U., Yabyt Perez M., Walmrath D., Grimminger F., Seeger W., Günther A. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and pneumonia. Am. J. Resp. Crit. Care Med. 2001; 163 (1): 95—100.

105. http://dx.doi.org/10.1164/ajrccm.163.1.9903029. PMID: 11208632

106. Seeger W., Günther A., Thede C. Differential sensitivity to fibrinogen inhibition of SPC vs. SPBbased surfactants. Am. J. Physiol. 1992; 262 (3 Pt 1): 286—291. PMID: 1550251

107. Seeger W., Stohr G., Wolf H.R. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J. Appl. Physiol. 1985; 58 (2): 326—338. PMID: 3838543

108. Günther A., Schmidt R., Harodt J., Schmehl T., Walmrath D., Ruppert C., Grimminger F., Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact of biophysical and biochemical surfactant properties. Eur. Respir. J. 2002; 19 (5): 797—804. PMID: 12030716

109. Hohlfeld J.M. Potential role of surfactant in asthma. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 44—45.

110. Cheng G., Ueda T., Sugiyama K., Toda M., Fukuda T. Compositional and functional changes of pulmonary surfactant in a guineapig model of chronic asthma. Respir. Med. 2001; 95 (3): 180—186. http://dx.doi.org/10.1053/rmed.2000.1012. PMID: 11266234

111. Cheng G., Ueda T., Numao T., Kuroki Y., Nakajima H., Fukushima Y., Motojima S., Fukuda T. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J. 2000; 16 (5): 831—835. http://dx.doi.org/10.1183/09031936.00.16583100. PMID: 11153579

112. Hohlfeld J.M. The role of pulmonary surfactant in asthma. Major com ponents of surfactant (functions). Respir. Res. 2002; 3: 4—12.

113. Kudo K., Sano H., Takahashi H., Kuronuma K., Yokota S., Fujii N., Shimada K., Yano I., Kumazawa Y., Voelker D.R., Abe S., Kuroki Y. Pulmonary collectins enhance phagocytosis of Mycobacterium avium through increased activity of mannose receptor. J. Immunol. 2004; 172 (12): 7592—7602. http://dx.doi.org/10.4049/jimmunol.172.12.7592.PMID: 15187139

114. Spragg R.G., Taut F.J., Lewis J.F., Schenk P., Ruppert C., Dean N., Krell K., Karabinis A., Günther A. Recombinant surfactant protein Cbased surfactant for patients with severe direct lung injury. Am. J. Respir. Crit. Care Med. 2011; 183 (8): 1055—1061. http://dx.doi.org/10.1164/rccm.2010091424OC. PMID: 21148720

115. Jang C.H., Cho Y.B., Oh S.E., Choi J.U., Park H., Choi C.H. Effect of nebulized bovine surfactant for experimental otitis vedia with effusion. Clin. Exp. Otorhinolaryngol. 2010; 3 (1): 13—17. http://dx.doi.org/10.3342/ceo.2010.3.1.13. PMID: 20379396

116. Rozenberg O.A., Danilov L.N., Volchkov V.A., Lebedeva E.S., Dubrovskaya V.F., Valkovich A.A., Klestova O.M., Kirillov Yu.A., Seiliev A.A., Shaldzhyan A.A., Loshakova L.V., Shulga A.E. Farmakologicheskie svoistva i terapevticheskaya aktivnost otechestvennykh preparatov legochnogo surfaktanta. [Pharmacological properties and therapeutic efficacy of the domestic preparations of lung surfactants]. Byulleten Eksperimentalnoi Biologii i Meditsiny. 1998; 126 (10): 455—458. PMID: 9825150. [In Russ.]

117. Taeusch H.W., Karen L.U., Ramierez Schrempp D. Improving pulmonary surfactants. Acta Pharmacol. Sin. 2002; 11: 15—18.

118. Günther A., Seeger W. Resistance to surfactant inactivation. In: Robertson B., Taeusch H.W. (eds.). Surfactant therapy for lung disease. Lung biology in health and disease. vol. 84. New York: Marcel Dekker Inc; 1995: 269—279.

119. Ikegami M., Agata Y., Elkady T., Hallman M., Berry D., Jobe A. Comparison of four surfactants: in vitro surface properties and respons es of preterm lambs to treatment at birth. Pediatrics. 1987; 79 (1): 38 46. PMID: 3642431

120. Seeger W., Stöhr G., Wolf H.R., Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J.Appl. Physiol. (1985). 1985; 58 (2): 326—338. PMID: 3838543

121. Prikaz Minzdrava RF № 318 “O perekhode na rekomendovannye Vsemirnoi Organizatsiei Zdravookhraneniya kriterii zhivorozhdeniya i mertvorozhdeniya” ot 4 dekabrya 1922 g. [Ministry of Health of the Russian Federation Order No. 318 "On transition to the live and still birth criteria recommended by the World Health Organization" dated December 4, 1992]. [In Russ.]

122. Nikitina T. Ekstremaly po zhizni. [Extreme life babies]. Moskovsky Komsomolets. 18.01.2012. http://ulan.mk.ru/article/2012/01/18/661578ekstremalyipozhizni.html. [In Russ.]

123. Barashnev Yu.I. Perinatalnaya nevrologiya. [Perinatal neurology]. Moscow: Triada — X; 2001: 640. [In Russ.]

124. Shnitkova E.V., Burtsev E.M., Novikov A.E., Filosofova M.S. Nervnopsikhicheskoe zdorovye detei, perenesshikh perinatalnoe porazhenie nervnoi sistemy. [Nervousmental health of children who had perinatal damage of the nervous system]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2000; 100 (3): 5759. PMID: 10758651. [In Russ.]

125. Arnold C. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. VermontOxford Neonatal Network. Pediatrics. 1996; 97 (1): 1—16. PMID: 8545199

126. Soll R., Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst. Rev. 2009; 1: CD000141. http://dx.doi.org/10.1002/14651858.CD000141.pub2. PMID: 19160177

127. Guardia C.G., Moya F.R., Sinha S., Simmons P.D., Segal R., GreenspanJ.S. A pharmacoeconomic analysis of inhospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa. J. Pediatr. Pharmacol. Ther. 2012; 17 (3): 220—227.

128. http://dx.doi.org/10.5863/1551677617.3.220. PMID: 23258964

129. Guardia C.G., Moya F.R., Sinha S., Gadzinowski J., Donn S.M., SimmonsP., Segal R. Reintubation and risk of morbidity and mortality in preterm infants after surfactant replacement therapy. J. Neonat. Perinat. Med. 2011; 4 (2): 101—109. http://dx.doi.org/10.3233/NPM20112736.

130. Velaphi S. Sravnenie effekta rannego i selektivnogo lecheniya respiratornogo distresssindroma (RDS) surfaktantom u novorozhdennykh. Kommentarii. Biblioteka Reproduktivnogo Zdorovya VOZ (poslednyaya redaktsiya: 1 sentyabrya 2010 g.). [Comparison of the effect of early and selective treatment for neonatal respiratory distress syndrome. Annotation. The WHO Reproductive Health Library (lastest revision, 1 September 2010)]. Geneva: WHO; 2010. [In Russ.]

131. Rusanov S.Yu., Cherdantseva G.A., Antonov A.G., Rozenberg O.A. Sravnitelnaya effektivnost endotrakhealnogo ingallyatsionnogo i mikrostruinogo vvedeniya surfaktantaBL v kompleksnom lechenii tyazhelogo RDS u nedonoshennykh novorozhdennykh. [Comparative efficiency of the endotracheal inhalation and microjet administrations of surfactantBL in the combination treatment of severe RDS in premature neonatal infants]. Rossiisky Vestnik Perinatologii i Pediatrii. 2003; 48 (1): 2631. [In Russ.]

132. Ionov O.V. Vysokochastotnaya ostsillyatornaya ventilyatsiya legkikh v kompleksnoi terapii tyazhelykh dykhatelnykh narushenii u novorozh dennykh s boleznyu gialinovykh membran i vrozhdennoi pnevmoniei: avtoref. dis. … kand. med. nauk. [Highfrequency oscillatory mechani cal ventilation in the combination therapy of severe respiratory disorders in newborn babies with hyaline membrane disease and congenital pneumonia. Abstract of Cand. Med. Sci. Thesis]. Moscow, 2003: 24. [In Russ.]

133. Perepelitsa S.A., Golubev A.M., Moroz V.V. Vliyanie ekzogennykh sur faktantov na pokazateli gazovogo sostava krovi u novorozhdennykh s respiratornym distresssindromom. Obshchaya Reanimatologiya. [Effects of exogenous surfuctants on the parameters of blood gas composition in neonatal respiratory distress syndrome. General Reanimatology]. 2007; 3 (3): 59—64. [In Russ.]

134. Krivchanskaya L.F., Rotaru D.I., Ieshanu V.I., Pynzar L.S., Brunk L.I. Bezopasnost i effektivnost profilakticheskogo i terapevticheskogobolyusnogo vvedeniya preparata SurfaktantBL. Materialy 1go Vserossiiskogo kongressa “Anesteziya i reanimatsiya v akusherstve i neonatologii”. Moskva, 2 — 5 dekabrya 2008 g. [The safety and efficiency of preventive and therapeutic bolus SurfactantBL administration. Proceedings of the 1st AllRussian Congress on Anesthesia and Resuscitation in Obstetrics and Neonatalogy. Moscow, 25 December 2008]. Moscow; 2008: 40. [In Russ.]

135. Volodin N.N. (red.). Printsipy vedeniya novorozhdennykh s respiratornym distresssindromom. Metodicheskie rekomendatsii. [Principles in the management of neonatal infants with respiratory distress syndrome. Guidelines]. Moscow; 2008: 24. [In Russ.]

136. Kolesnichenko A.P., Kuznetsova I.V., Aleksandrovich Yu.S. Metodicheskie rekomendatsii po vedeniyu novorozhdennykh s RDS. Obsuzhdeny i odobreny na 4m Mezhdunarodnom kongresse po respiratornoi podderzhke. Krasnoyarsk, 14 — 17 sentyabrya 2013 u. [Guidelines for the management of neonatal infants with respiratory distress syndrome. Discussed and approved at the 4th International Congress on Respirtory Support. Krasnoyarsk, 1417 September 2013]. Krasnoyarsk; 2013: 36. [In Russ.]

137. Volodin N.N. (red.). Vedenie novorozhdennykh s respiratornym dis tress sindromom. Metodicheskie rekomendatsii. [Management of neonatal respiratory distress syndrome. Guidelines]. Moscow; 2014: 72. [In Russ.]

138. Nesterova L.A., Panchenko A.S., Basalkevich M.A., Kolycheva E.V., Tikhonenko O.A., Rogaleva T.E. Bronkholegochnaya patologiya u nedonoshennykh detei s primeneniem ekzogennogo surfaktanta “Kurosurf”. [Use of the exogenous surfactant Curosurf in premature babies with bronchopulmonary disease]. Zabaikalsky Meditsinsky Vestnik. 2006; 2: 10—12. [In Russ.]

139. Nemets V.D., Timofeyeva O.A., Koptseva A.A., Tyumentseva A.A. Bolyusnoe vvedenie SurfaktantaBL dlya lecheniya legochnoi patologii novorozh dennykh, obuslovlennoi vtorichnym defitsitom surfaktanta. Materialy 1 go Vserossiiskogo kongressa “Anesteziya i reanimatsiya v akusherstve i neonatologii”. Moskva, 2—5 dekabrya 2008 g. [Bolus SurfactantBL administration for the treatment of neonatal lung disease caused by sec ondary surfactant deficiency. Proceedings of the 1st AllRussian Congress on Anesthesia and Resuscitation in Obstetrics and Neonatalogy. Moscow, 25 December 2008]. Moscow; 2008: 42—43. [In Russ.]

140. Vinogradova I.V., Nikiforova G.I. Primenenie Surfaktanta BL u novorozhdennykh s sindromom aspiratsii mekoniya. [Use of SurfactantBL in neonatal infants with meconium aspiration syndrome]. Rossiisky Vestnik Perinatologii i Pediatrii. 2011; 56 (4): 1519. [In Russ.]

141. Nemets V.D., Koptseva A.A., Tyumentseva A.A., Kotov P.V. Kontseptsiya “otkrytykh legkikh” i surfaktantterapiya respiratornogo distresssin droma novorozhdennykh. Materialy 3go Vserossiiskogo kongressa“Anesteziya i reanimatsiya v akusherstve i neonatologii”. Moskva, 27 —

142. noyabrya 2012 g. [The open lung concept and surfactant therapy for neonatal respiratory distress syndrome. Proceedings of the 3rd All Russian Congress on Anesthesia and Resuscitation in Obstetrics and Neonatalogy. Moscow, 2730 November 2012]. Moscow; 2012: 93—95. [In Russ.]

143. Romanenko V.A., Romanenko K.V., Rozenberg O.A., Bogachev N.Yu., Averin A.P. Otsenka effektivnosti otechestvennogo surfaktanta v kompleksnom lechenii dykhatelnoi nedostatochnosti u novorozhdennykh detei. [Evaluation of a Russian surfactant in the combination treat ment of neonatal respiratory failure]. Rossiisky Vestnik Perinatologii i Pediatrii. 2001; 46 (1): 22—25. [In Russ.]

144. Perepelitsa S.A., Golubev A.M., Moroz V.V. Respiratornyi distresssin drom novorozhdennykh: rannyaya diagnostika, profilaktika, lechenie. Obshchaya Reanimatologiya. [Neonatal respiratory distress syndrome: early diagnosis, preventation, and treatment. General Reanimatology]. 2012; 8 (3): 95102. [In Russ.]

145. Kusuda S., Fujimura M., Sakuma I., Aotani H., Kabe K., Itani Y., Ichiba H., Matsunami K., Nishida H.; Neonatal Research Network, Japan. Morbidity and mortality of infants with very low birth weight in Japan: center variation. Pediatrics. 2006; 118 (4): e1130—e1138. http://dx.doi.org/10.1542/peds.20052724. PMID: 16950943

146. Laughon M., Bose C., Moya F., Aschner J., Donn S.M., Morabito C., Cummings J.J., Segal R., Guardia C., Liu G.; Surfaxin Study Group. Surfaxin Study Group. A pilot randomized, controlled trial of later treatment with a peptidecontaining, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics 2009; 123 (1): 89—96. http://dx.doi.org/10.1542/peds.20072680. PMID: 19117865

147. Ryndin A.Yu., Antonov A.G. Sposob profilaktiki bronkholegochnoi displazii u novorozhdennykh s ochen nizkoi i ekstremalno nizkoi massoi tela pri rozhdenii. Patent RF na izobretenie №2416388. [A procedure for prevention of bronchopulmonary dysplasia in very low and extremely low birth weight neonatal infants. RF patent for invention No. 2416388]. [In Russ.]

148. Vinogradova I.V., Belova A.N., Vinogradov D.A., Volchkov V.A., Seiliev A.A., Rozenberg O.A. Kogda nachinat profilaktiku BLD u novorozh dennykh s pomoshchyu surfaktantterapii? Materialy 3goVserossiiskogo kongressa «Anesteziya i reanimatsiya v akusherstve i neonatologii». Moskva, 27—30 noyabrya 2012 g. [When should surfactant therapy start for the prevention of BPD in neonates? Proceedings of the 3rd AllRussian Congress on Anesthesia and Resuscitation in Obstetrics and Neonatalogy. Moscow, 2730 November 2012]. Moscow; 2012: 27—29. [In Russ.]

149. Perepelitsa S.A., Luchina A.A. Inhalation surfactant therapy of newborn infants with prolonged artificial lung ventilation. Internationaler Kongress Fachmesse. Hanover, 5—6 June 2014. 124126.


Для цитирования:


Розенберг О.А. ПРЕПАРАТЫ ЛЕГОЧНОГО СУРФАКТАНТА ПРИ ОСТРЫХ И ХРОНИЧЕСКИХ ЗАБОЛЕВАНИЯХ ЛЕГКИХ (Часть I). Общая реаниматология. 2014;10(4):51-73. https://doi.org/10.15360/1813-9779-2014-4-51-73

For citation:


Rozenberg O.A. Pulmonary Surfactants for Acute and Chronic Lung Diseases (Part I). General Reanimatology. 2014;10(4):51-73. (In Russ.) https://doi.org/10.15360/1813-9779-2014-4-51-73

Просмотров: 678


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1813-9779 (Print)
ISSN 2411-7110 (Online)